Key result
48-hour neuron-specific enolase strongly predicts 30-day poor neurological outcome with 100% specificity.
Why the study?
Neuron-specific enolase (NSE) has strong prognostic value for neurologic outcome after sudden cardiac arrest, but a universal threshold is lacking despite recommended cutoffs in the 2025 European Resuscitation Council Guidelines.
Does neuron-specific enolase (NSE) measured at 24, 48, and 72 hours after ROSC accurately predict 30-day poor neurological status (CPC 3-5) and disability (mRS ≥4) in comatose cardiac intensive care unit patients after cardiac arrest?
Cohort (n=94)
Does neuron-specific enolase (NSE) measured at 24, 48, and 72 hours after ROSC accurately predict 30-day poor neurological status (CPC 3-5) and disability (mRS ≥4) in comatose cardiac intensive care unit patients after cardiac arrest?
In a CICU cardiac arrest cohort, 48-hour neuron-specific enolase (NSE) had high prognostic accuracy (AUC 0.89) for 30-day poor neurological outcome, achieving 100% specificity and positive predictive value at a cutoff of 48.5 ng/mL, which is slightly lower than the current >60 ng/mL guideline threshold.
Background Neuron-specific enolase (NSE) is a biomarker of neuronal injury with strong prognostc value for neurologic outcome after sudden cardiac arrest (CA). Recommended cutoffs in the 2025 European Resuscitation Council (ERC) Guidelines derive from several studies, but a universal threshold is lacking. Purpose To evaluate NSE performance as a prognostic predictor in CA intensive care unit (CICU) cohort; to define optimal NSE cutoffs, comparing with guideline-recommended values. Methods Retrospective analysis of consecutive CICU patients admitted after in-hospital or out-of-hospital CA (IHCA or OHCA), between 2015-2025. Comatose patients (GCS<8) with multimodal neuroprognostication and NSE at 24, 48, and 72 hours after ROSC were included. Neuroprognosis followed ERC criteria. Neurological status at 30 days was classified according to the Cerebral Performance Category (CPC) scale, as good (CPC 1-2) or poor (CPC 3–5), and disability by modified Rankin Scale (mRS). ROC curves identified optimal NSE cutoffs for CPC 3-5 and mRS≥4 and estimated positive predictive value (PPV). Results 94 patients (mean age 62 ± 17 y, 66% male) were included, 32% had ICHA and 68% OHCA. Mean no-flow time was 1.8, median low-flow time was 15 [8.5-18.8], and time to ROSC 25 [16-40] min. A shockable rhythm was present in 65%, 70% underwent coronary angiography, and 6% had a non-cardiac cause for CA. Among 90 patients completing neuroprognostication, a third had poor prognosis, 37% were indeterminate, and 7% were brain dead. At 30 days, 71% had CPC 3-5, and 68% significant functional dependence (mRS≥4). Mortality at 30 days was 62%. Median NSE values at 24, 48 and 72 hours were 49 [32-91], 45 [25-122] and 41 [23-101] ng/mL, respectively. NSE values were significantly higher in patients with very likely poor neuroprognosis; and in CPC 3-5 (122 vs 39, p=0.0005, 162 vs 32, p <0.0001 and 145 vs 28, p = 0.0005; 58 vs 36, p=0.007, 46 vs, p =0.0001 and 45 vs 22, p = 0.005; respectively). NSE at 48h showed highest accuracy for predicting poor CPC and mRS≥4 (AUC 0.89, p<0.001). The optimal 48h cutoff of 25 ng/mL (Youden index) yielded 72–75% specificity, 89% sensitivity and 91–92% PPV. Higher 48h NSE values further increased PPV, with 48.5 ng/mL providing 100% PPV and specificity but 54% sensitivity. NSE at 24 and 72 h also performed well (AUC>0.7, p<0.05). A 48 h level >60 ng/mL, as currently recommended, had 100% PPV for CPC 3–5 and mRS≥4. Conclusion(s) In this CICU CA cohort, NSE showed good prognostic performance at all recommended time points, with maximal accuracy at 48h. A cutoff of 48.5ng/mL at 48 hours was the most accurate for predicting poor CPC and mRS ≥4 at 30 days, slightly lower than guideline-recommended values, suggesting population-dependent cutoffs and reinforcing the importance of multimodal neuroprognostication.ROC
No takes yet. Share an insight, caveat, or question.
Matias et al. (2026) conducted a cohort in Sudden cardiac arrest (n=94). Neuron-specific enolase (NSE) levels at 24, 48, and 72 hours after ROSC vs. ERC guideline-recommended NSE cutoffs (>60 ng/mL) was evaluated on Poor neurological status (CPC 3-5) and significant functional dependence (mRS ≥4) at 30 days (AUC 0.89, p=<0.001). Neuron-specific enolase at 48h strongly predicted 30-day poor neurological outcome (AUC 0.89, p<0.001), with a 48.5 ng/mL cutoff yielding 100% PPV and specificity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: